
Serplulimab Yields Sustained OS/PFS Benefits in Extensive-Stage SCLC
Combining serplulimab (Hetronifly) with chemotherapy as frontline treatment conferred sustained overall survival (OS) and progression-free survival (PFS) benefits vs placebo plus chemotherapy among patients with extensive-stage small cell lung cancer (ES- …